

Table 1. COVID-19 Vaccination Guidance by Immunocompromised Population^[2-8]

Group	Suggested timing of 2026-2027 COVID-19 vaccine ^{*,**}
Solid organ transplant	At least 2 weeks pre-SOT; or ≥3 months post-SOT
Hematologic malignancy	- Optimal timing includes ≥2 weeks before starting treatment and ≥ 3 months after last infusion - For B-cell depletion, consider ≥3-6 months after last infusion - If optimal timing not feasible, administer during treatment (blunted immune response likely)
HCT/CAR-T	- Optimal timing includes ≥3 months after transplant or CAR-T treatment - For B-cell depletion, consider ≥3-6 months after last infusion - If optimal timing not feasible, administer during treatment (blunted immune response likely)
Solid tumor chemotherapy	At least 2 weeks before starting therapy; during/after is acceptable
Primary Immuno-deficiency	Align with IVIG/SCIG or clinic access
Autoimmune immunosuppression	- Optimal timing includes ≥2 weeks before starting treatment and ≥ 3 months after last infusion - For B-cell depletion, consider ≥3-6 months after last infusion - If optimal timing not feasible, administer during treatment (blunted immune response likely)
HIV	Align with preventive routine care

*Defer during acute transplant rejection treatment or severe/acute illness

**Use shared-decision making for early windows based on levels of community virus circulation